1. Introduction {#sec1}
===============

Red ginseng (RG), which is the steamed root of *Panax ginseng* Meyer (family Araliaceae), has been used widely as a dietary supplement and as a traditional Chinese medical treatment for cancer, diabetes, and inflammatory diseases [@bib1], [@bib2], [@bib3]. RG contains ginsenosides Rb1, Rg1, Re, Rc, Rb2, and Rd, which are components of white ginseng, and Rg3, which is a characteristic constituent [@bib4], [@bib5]. Among these, ginsenosides Rb1, Rc, Rb2, Rd, and Rg3 are categorized as protopanaxadiol ginsenosides [@bib6]. These protopanaxadiol ginsenosides exhibit a variety of pharmacological activities, such as antitumor, antidiabetic, antiinflammatory, and neuroprotective activities [@bib7], [@bib8], [@bib9], [@bib10], [@bib11]. When RG is administered orally, the polar ginsenosides Rb1, Rb2, and Rc can be metabolized to nonpolar ginsenoside 20-*O*-*β*-(D-glucopyranosyl)-20(S)-protopanaxadiol, which is called compound K (CK), through ginsenoside Rd; or ginsenoside Rg3 can be metabolized to protopanaxadiol through ginsenoside Rh2 by the gut microbiota [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]. In a previous study, when RG was orally administered to mice, ginsenosides Rd, Rg3, and CK were detected mainly in the plasma [@bib20], [@bib21]. In addition, CK has been detected in the blood of healthy volunteers treated with ginseng or ginsenoside Rb1 [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]. These nonpolar ginsenoside metabolites of ginsenosides Rd, Rg3, and CK are known to exhibit more potent biological activities, including antitumor and antiinflammatory activities both *in vitro* and *in vivo* than their parent ginsenosides [@bib29], [@bib30]. Based on these findings, to increase the pharmacological activity of RG, various bioactive ginsenoside-enforcing products have been developed, such as heat-processed, microwave-treated, enzyme-treated, and fermented ginseng products [@bib21], [@bib31], [@bib32], [@bib33], [@bib34]. Heat treatments such as steaming mainly produce ginsenoside Rg3 by removing a diglucoside at the C20 position, whereas bacterial enzymes are involved in glycosidic bond hydrolysis to eliminate the terminal monosaccharide ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Transformation pathways of protopanaxadiol-type ginsenosides by steaming and gut microbiota. CK, compound K; PPD, protopanaxadiol.Fig. 1

As mentioned previously, the gut microbiota may play an important role in exerting the pharmacological activity of ginseng by converting the polar ginsenosides to nonpolar bioactive ginsenosides. There are many articles reporting the pharmacokinetics of ginsenosides after the administration of ginseng or ginsenosides [@bib20], [@bib21], [@bib23], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41]. However, information about the pharmacokinetic parameters of various ginsenoside metabolites in humans after intake of RG is still limited. Moreover, the roles of the gut microbiota on the pharmacokinetics of ginsenosides in humans have not yet been fully elucidated, although it is well recognized that ginsenosides can be metabolized by the enzymes of gut microbes.

In this study, we investigated the pharmacokinetic properties of the protopanaxadiol ginsenosides, including Rd, Rg3, F2, and CK, in humans after the intake of conventional RG and fermented red ginseng (FRG). Then, we analyzed the relationships between the pharmacokinetic profiles of the ginsenoside metabolites and ginsenoside-metabolizing activity of human fecal microbiota.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Ginsenoside standards for Rg3, Rd, F2, and CK (purity ≥98%) were obtained from ChemFaces (Wuhan, China). RG and FRG were donated as a paste form from Korea Yakult Research Institute (Yongin, Korea) [@bib20]. Digitoxin as an internal standard (IS) and formic acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). Acetonitrile and methanol (HPLC grade) were purchased from J.T. Baker (Phillipsburg, NJ, USA). Distilled water was prepared using a Milli-Q purification system (Millipore, Billerica, MA, USA). The Oasis HLB 96-well solid-phase extraction (SPE) cartridge was purchased from Waters (Milford, MA, USA).

2.2. Participants {#sec2.2}
-----------------

Physically healthy men and women, aged between 20 and 45 years, were recruited from H Plus Yangji Hospital (Seoul, Korea). Participants were recruited if antibacterial, antidiarrhea, and laxative medications were not given within 1 month before the study. The study protocol and consent forms were approved by the Institutional Review Boards of H Plus Yangji Hospital, and all participants provided written informed consent to participate in the study. All study procedures were conducted in compliance with the principles of the Declaration of Helsinki and Korean Good Clinical Practice guidelines (IRB HYJ-18-011).

2.3. Study design {#sec2.3}
-----------------

RG or FRG (3 g) was orally administered to volunteers once a day for 3 days to acclimatize to RG or FRG. The volunteers were admitted to the hospital 2 days after the final administration and were randomly assigned to receive RG or FRG. The RG group consisted of 13 men and 4 women, and the FRG group consisted of 13 men and 5 women. All volunteers were given standardized meals, and no food intake was permitted after 20:00 pm. The next day, the volunteers orally received 3 g of either RG or FRG with 47 mL of tap water. Any food or water intake was not allowed during the first 4 h after administration of ginseng extracts. Venous blood samples (10 mL) were collected before the administration and at 1, 3, 6, 9, 12, and 24 h after the administration of RG or FRG in dry nonheparinized centrifuge tubes. Serum was collected by centrifugation at 10,000 × g for 5 min.

2.4. HPLC analysis of ginsenosides {#sec2.4}
----------------------------------

The RG and FRG samples were determined by an Agilent 1200 series HPLC system with a UV detector (Agilent Technologies, Palo Alto, CA, USA). The chromatographic separation of ginsenosides was achieved using a Discovery C18 column (4.6 × 250 mm, 5 μm; Sigma-Aldrich, MO, USA). The mobile phase consisted of water (solvent A) and acetonitrile (solvent B). The mobile phase flow rate was 1 mL/min. The solvent composition was initially set at 15% B solvent, with gradient elution as 0--5 min, 15%; 5--17 min, 20%; 17--57 min, 39%; 57--70 min, 48%; 70--80 min, 70%; 80--82 min, 90%; 82--94 min, 15%; and 94--115 min, 15% of solvent B. The injection volume was 10 μL, and the UV detection wavelength was set at 203 nm.

2.5. Preparation of calibration standards and quality control samples {#sec2.5}
---------------------------------------------------------------------

Stock solutions of Rd, Rg3, F2, and CK were prepared to obtain a concentration of 1 mg/mL in methanol. Working standard solutions were prepared by diluting the stock solution with methanol to final concentration ranges: 0.2--30 ng/mL for Rg3, F2, and CK and 0.5--30 ng/mL for Rd. The IS solution was digitoxin dissolved in methanol at a concentration of 200 ng/mL. These working standard solutions (10 μL) were spiked to blank human serum (1 mL) to yield calibration standards of range from 0.2 ng/mL to 30 ng/mL for Rg3, F2, and CK and from 0.5 ng/mL to 30 ng/mL for Rd. Quality control (QC) samples were prepared at a final concentration of 0.2 ng/mL \[low-level QC (LQ)\], 3 ng/mL \[(medium-level QC (MQ)\], and 10 ng/mL \[high-level QC (HQ)\] for Rg3, F2, and CK and 0.5 ng/mL (LQ), 3 ng/mL (MQ), and 10 ng/mL (HQ) for Rd.

2.6. Sample preparation {#sec2.6}
-----------------------

Human serum samples (1 mL) were mixed with 100 μL of IS solution and prepared for loading in the SPE cartridge. Activating the SPE cartridge was done by washing it with 1 mL of methanol. The cartridges were equilibrated and washed twice with 1 mL distilled water and eluted with 1 mL methanol. The eluate was dried under a flow of nitrogen at 35°C. The residue was dissolved in 100 μL of methanol and centrifuged for LC--MS/MS analysis.

2.7. LC--MS/MS instrumentation {#sec2.7}
------------------------------

All samples were separated from the matrix components using a Thermo Hypersil Gold column (2.1 × 50 mm, 3 μm; Thermo Fisher Scientific, Bellefonte, PA, USA). The mobile phase consisted of 0.1% formic acid in distilled water (solvent A) and 0.1% formic acid in acetonitrile (solvent B). A gradient program was used for HPLC separation, with a flow rate of 0.3 mL/min. The initial composition of the mobile phase was 10% solvent B, which was changed to 40% solvent B over 2.0 min and 90% solvent B over 5.0 min and followed by 11 min reequilibration to the initial condition over 0.1 min. The ginsenosides Rg3, Rd, F2, and CK were measured using an Agilent 6460 triple quadrupole tandem mass spectrometer in a multiple reaction monitoring mode using positive/negative electrospray ionization source. The precursor--product ion pairs monitored were 829.5→783.4 for Rg3 and F2, 969.5→789.4 for Rd, and 667.4→621.3 for CK. Nitrogen gas was used as a nebulizer at a pressure of 35 psi, as a carrier gas at 10 L/min (at 300*°*C), and as a sheath gas at 11 L/min (at 350°C).

2.8. Linearity, accuracy, and precision {#sec2.8}
---------------------------------------

Calibration curves were generated by plotting the peak area ratio of the analyte to the IS versus the concentration of the analyte, using least-square linear regression. The intraday and interday accuracy and precision of the assay were evaluated by repeated analyses of samples at LQ, MQ, and HQ for three consecutive days.

2.9. Pharmacokinetic analysis {#sec2.9}
-----------------------------

The Phoenix WinNonlin Enterprise program (version 5.3; Pharsight Inc., St. Louis, MO, USA) was used with a noncompartmental statistical model to determine the following pharmacokinetic parameters: C~max~ (maximum serum concentration), T~max~ (the time taken to reach maximum), AUC~t~ (the area under curve from zero to the last time point), AUC~∞~ (the area under curve from zero to infinity), and t~1/2~ (elimination half-life).

2.10. Assay of fecal ginsenoside Rd-- and CK--forming activity {#sec2.10}
--------------------------------------------------------------

The human fecal specimens (approximately 0.2 g) were collected in plastic cups after 1--12 h, suspended with 1.8 mL cold saline, and centrifuged at 500 × g for 5 min [@bib20], [@bib21]. The supernatant were further centrifuged at 10,000 × g for 30 min, and the resulting precipitate was suspended in 5 mL of phosphate buffered saline (PBS), sonicated, and centrifuged at 10,000 × g for 30 min. The resulting supernatant was used as a crude fecal enzyme solution. For the fecal metabolizing activities, the reaction mixture (2 mL) containing 0.2 mL of the crude enzyme solution and 0.2 mL of 0.1 mg/mL RG extract was incubated at 37*°*C for 12 h, and the reaction was stopped by the addition of 2 mL of MeOH. The reaction mixture is centrifuged at 3000 × g for 10 min, and the levels of ginsenosides Rd, F2, and CK in the resulting supernatant are analyzed by HPLC. Ginsenoside Rd--forming activity was indicated as the amount required to catalyze the formation of 1.0 nmole of ginsenosides Rd, F2, and CK from the RG extract per hour under the standard assay conditions. CK-forming activity was indicated as the amount required to catalyze the formation of 1.0 nmol of ginsenoside CK from the RG extract per hour under the standard assay conditions. Specific activity was defined as nmol/h per g of feces.

2.11. Statistics {#sec2.11}
----------------

All pharmacokinetic (PK) data were summarized as mean ± standard deviation. A one-way analysis of variance followed by the Student t-test was conducted to compare the means of different groups using SPSS (version 24; IBM Corporation, Armonk, NY, USA). Spearman\'s rank correlation analysis was conducted using SPSS to determine the correlation coefficient between the area under the serum concentration--time curve (AUC) of ginsenosides and fecal bacterial ginsenoside-forming activity. A p-value less than 0.05 was considered to be statistically significant.

3. Results and discussion {#sec3}
=========================

3.1. Contents of ginsenosides in RG and FRG extracts {#sec3.1}
----------------------------------------------------

Ginsenosides of RG and FRG were quantified using HPLC. The contents of ginsenosides Rb1, Rd, Rg3, F2, and CK were 16.06 mg/g, 3.24 mg/g, 0.71 mg/g, 0.20 mg/g, and \<0.40 mg/g, respectively, in RG; and 11.46 mg/g, 11.84 mg/g, 0.79 mg/g, 0.23 mg/g, and 0.42 mg/g, respectively, in FRG.

3.2. Bioanalytical method for ginsenosides {#sec3.2}
------------------------------------------

The serum concentrations of ginsenosides Rd, F2, Rg3, and CK were determined using LC-MS/MS analysis. A quantitative method for ginsenosides in the human serum sample was developed and validated. The calibration curve equations were y = 0.0527x -- 0.0063 for Rg3; y = 0.0131x + 0.0009 for F2; y = 0.0152x + 0.0050 for CK; and y = 0.0076x -- 0.0023 for Rd. The correlation coefficients of the calibration curves were more than 0.99. The intraday and interday precisions were found to be \<12.6%, \<13.3%, \<11.8%, and \<12.6%, and the accuracies were 86.1--114.6%, 87.9--110.2%, 89.8--106.0%, and 93.5--107.7% for Rg3, F2, CK, and Rd, respectively.

3.3. Pharmacokinetic profiles of ginsenosides Rd, F2, Rg3, and CK in the healthy volunteers {#sec3.3}
-------------------------------------------------------------------------------------------

Ginseng contains hydrophilic protopanaxadiol ginsenosides Rb1, Rb2, and Rc as principal bioactive constituents. When ginseng is administered orally, portions of these hydrophilic protopanaxadiol ginsenosides are metabolized to ginsenosides Rd, F2, and CK by the gut microbiota. A variety of gut bacteria that belong to *Bifidobacterium, Eubacterium, Fusobacterium*, and *Bacterodies* are known to be involved in the biotransformation of ginsenosides ([Fig. 1](#fig1){ref-type="fig"}) [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22]. When fresh ginseng is steamed to prepare RG, portions of ginsenosides Rb1, Rb2, and Rc are transformed to ginsenoside Rg3 ([Fig. 1](#fig1){ref-type="fig"}) [@bib17], [@bib20], [@bib21], [@bib22], [@bib34]. The FRG was prepared by probiotic fermentation with *Bifidobacterium lactis* HY8002 and *Bifidobacterium adolescentis* HY8502 [@bib20]. Thus, microbial metabolism facilitated the biotransformation of the polar ginsenosides to ginsenoside Rd and consequently enriched the ginsenoside Rd contents when compared with RG.

The mean serum concentration--time curves of ginsenosides Rd, F2, Rg3, and CK are presented in [Fig. 2](#fig2){ref-type="fig"}, and the pharmacokinetic parameters are summarized in [Table 1](#tbl1){ref-type="table"}. The C~max~ values of Rd, F2, Rg3, and CK were 1.77 ± 2.09 ng/mL, 0.68 ± 0.32 ng/mL, 4.32 ± 2.81 ng/mL, and 4.57 ± 3.16 ng/mL, respectively, for the RG group. The AUC~∞~ values of Rd, F2, Rg3, and CK were 8.20 ± 11.95 ng·h/mL, 4.54 ± 3.70 ng·h/mL, 36.40 ± 19.68 ng·h/mL, and 40.30 ± 29.83 ng·h/mL, respectively, for the RG group. For the FRG group, the C~max~ values of Rd, F2, Rg3, and CK were 16.69 ± 6.95 ng/mL, 2.79 ± 4.29 ng/mL, 4.83 ± 5.92 ng/mL, and 13.93 ± 15.17 ng/mL, respectively. The AUC~∞~ values of Rd, F2, Rg3, and CK for the FRG group were 187.90 ± 95.87 ng·h/mL, 30.24 ± 41.87 ng·h/mL, 28.68 ± 14.27 ng·h/mL, and 137.01 ± 96.16 ng·h/mL, respectively. The extract contents and AUC values of each ginsenoside are presented in [Fig. 3](#fig3){ref-type="fig"}. The range of T~max~ values of each ginsenoside for all the participants is depicted in [Fig. 4](#fig4){ref-type="fig"}. The mean T~max~ value of Rg3 was 5.69 ± 3.38 h, and the mean T~max~ values of Rd, F2, and CK were 9.41 ± 4.42 h, 9.32 ± 3.38 h, and 10.35 ± 4.06 h, respectively. Statistically significant differences in the pharmacokinetic parameters between the men and women were not observed in either group.Fig. 2Mean serum concentration-time profiles of ginsenosides in health volunteers after oral administration of RG and FRG. (A) Ginsenoside Rd, (B) ginsenoside F2, (C) ginsenoside Rg3, and (D) compound K. FRG, fermented red ginseng; RG, red ginseng.Fig. 2Table 1Pharmacokinetic parameters of ginsenosides Rd, F2, Rg3, and CK in healthy volunteers orally treated with RG or FRGTable 1GinsenosideParameterRG group (n = 17)FRG group (n = 18)Total (n = 17)Male (n = 13)Female (n = 4)Total (n = 18)Male (n = 13)Female (n = 5)RdC~max~ (ng/mL)1.77 ± 2.091.53 ± 2.182.55 ± 1.8116.69 ± 6.9517.52 ± 6.5814.53 ± 8.18AUC~t~ (ng·h/mL)7.85 ± 11.246.93 ± 11.3910.83 ± 11.78163.82 ± 77.56167.83 ± 75.03153.38 ± 92.12AUC~∞~(ng·h/mL)8.20 ± 11.956.93 ± 11.3912.30 ± 14.60187.90 ± 95.87190.75 ± 101.98180.48 ± 88.12T~max~ (h)15.12 ± 9.356.67 ± 4.558.33 ± 7.0210.50 ± 3.889.92 ± 3.3312.00 ± 5.20F2C~max~ (ng/mL)0.68 ± 0.320.57 ± 0.221.03 ± 0.392.79 ± 4.293.09 ± 5.032.01 ± 1.14AUC~t~ (ng·h/mL)4.33 ± 3.252.98 ± 2.018.70 ± 2.6127.17 ± 37.2529.17 ± 43.2421.98 ± 15.51AUC~∞~(ng·h/mL)4.54 ± 3.703.08 ± 2.249.28 ± 3.7130.24 ± 41.8732.98 ± 48.5923.13 ± 16.68T~max~ (h)8.76 ± 5.526.85 ± 3.1812.75 ± 4.5010.83 ± 3.2810.15 ± 3.5810.80 ± 2.68Rg3C~max~ (ng/mL)4.32 ± 2.814.43 ± 3.023.97 ± 2.334.83 ± 5.925.83 ± 6.742.25 ± 0.96AUC~t~ (ng·h/mL)35.63 ± 18.6935.27 ± 20.7336.80 ± 11.8627.34 ± 14.1131.04 ± 14.9717.71 ± 3.72AUC~∞~(ng·h/mL)36.40 ± 19.6836.14 ± 21.8837.23 ± 12.2228.68 ± 14.2732.24 ± 14.9719.41 ± 6.72T~max~ (h)6.00 ± 3.525.54 ± 3.847.50 ± 1.735.39 ± 3.425.85 ± 3.854.20 ± 1.64CKC~max~ (ng/mL)4.57 ± 3.163.80 ± 2.987.09 ± 2.5813.93 ± 15.179.99 ± 10.9424.18 ± 20.91AUC~t~ (ng·h/mL)39.04 ± 28.8530.49 ± 25.6066.83 ± 21.72111.54 ± 84.7094.80 ± 76.77155.04 ± 97.63AUC~∞~(ng·h/mL)40.30 ± 29.8331.31 ± 26.3369.52 ± 21.98137.01 ± 96.16128.10 ± 97.96160.20 ± 97.89T~max~ (h)10.69 ± 2.8910.50 ± 3.0011.25 ± 2.8710.06 ± 5.0310.92 ± 5.667.80 ± 1.64[^2]Fig. 3Contents of ginsenosides in extracts and their AUCs in PK studies. (A) Contents of ginsenosides in RG and FRG extracts; (B) AUCs of ginsenosides in the RG- and FRG-treated groups. AUC, area under the serum concentration--time curve; FRG, fermented red ginseng; RG, red ginseng.Fig. 3Fig. 4Box plot of T~max~ for ginsenosides Rg3, Rd, F2, and CK in all participants. \*\*P \< 0.01. The circle represents the outlier data points. CK, compound K; T~max~, the time taken to reach maximum.Fig. 4

After the RG or FRG intake, the mean AUC values of ginsenosides Rd, F2, and CK in the FRG group were 187.90 ± 95.87 ng·h/mL, 30.24 ± 41.87 ng·h/mL, and 137.01 ± 96.16 ng·h/mL, respectively, and those in the RG group were 8.20 ± 11.95 ng·h/mL, 4.54 ± 3.70 ng·h/mL, and 40.30 ± 29.83 ng·h/mL, respectively, which were significantly higher than those in the RG group, even when considering the differences in the ginsenoside contents of each extract. The ginsenoside Rd amount in the FRG group (11.84 mg/g) was approximately 3.5 times higher than that in the RG group (3.24 mg/g), but the mean AUC value of ginsenoside Rd in the FRG group was more than 20 times higher than that in the RG group. In addition, the contents of ginsenosides F2 and CK were very low and comparable in RG and FRG extracts. However, the AUC values of ginsenosides F2 and CK in the FRG group were more than six and three times higher, respectively, than those in the RG group. The greater ginsenoside Rd absorption in the FRG group suggests the additional formation of ginsenoside Rd, possibly from other polar ginsenosides after the FRG intake. The FRG that was administered may have contained some of the probiotics that were used for the fermentation. The probiotics may not have been alive, but they could have acted as prebiotics. Thus, probiotics may activate the metabolic activity of the gut microbiota to promote the formation of ginsenoside Rd. In turn, this increase in the ginsenoside Rd formation may have enhanced the biotransformation into ginsenosides F2 and CK. These sequential reactions may have resulted in the increase in the nonpolar ginsenosides in the FRG group.

There was no difference in the AUC values of ginsenoside Rg3 between the two groups. As shown in [Fig. 1](#fig1){ref-type="fig"}, ginsenoside Rg3 is known to be generated by heat processing, such as steaming, rather than microbial biotransformation. The data from the FRG group revealed that ginsenoside Rg3 was not likely generated from ginsenoside Rd or the other polar ginsenosides via the gut microbiota enzymes. The T~max~ profiles of Rg3 also support this. When ginseng is taken orally, the polar ginsenosides are metabolized to hydrophobic ginsenosides by the gut microbiota, and then, they are absorbed into the blood. Consequently, it should take longer for the hydrophobic ginsenosides to be absorbed. According to [Fig. 4](#fig4){ref-type="fig"}, the T~max~ values of Rd, F2, and CK reached mostly no sooner than 6 h after the dosing. This indicates that Rd, F2, and CK were generated by gut metabolism, and then, they were absorbed, rather than being absorbed directly from the ginseng extracts that were taken. However, the T~max~ values of Rg3 were somewhat earlier (approximately 3 to 6 h) than those of the other three ginsenosides. This shows that Rg3 was mainly absorbed directly from the ginseng extracts that were taken. The portion of Rg3 that was absorbed after the biotransformation of the polar ginsenosides into Rg3 by the gut microbiota metabolism was assumed to be minimal. Actually, studies have mainly reported that polar ginsenosides including ginsenoside Rb1 are transformed into CK by the intestinal microflora [@bib17], [@bib34], [@bib42], [@bib43], whereas the metabolism into ginsenoside Rg3 by gut microbiota was not demonstrated. According to Kong et al, the deglycosylation of ginsenosides by gut microbiota mainly occurs at the, C3 position whereas the deglycosylation under acidic conditions takes place at the C20 position. These observations may partially support our deduction mentioned previously [@bib44].

3.4. Fecal ginsenoside Rd-- and CK--forming activities {#sec3.4}
------------------------------------------------------

To understand the relationships between the serum concentration levels of the ginsenosides and the ginsenoside-metabolizing activities of the gut microbiota, we measured the fecal ginsenoside Rd-- and CK--forming activities of the study participants ([Table 2](#tbl2){ref-type="table"}). The ginsenoside Rd--forming activity was 51.65 ± 27.24 nmol/g/h in all the participants; it was 46.91 ± 26.15 nmol/g/h in the men and 66.15 ± 24.9 nmol/g/h in the women. The CK-forming activity was 29.02 ± 25.70 nmol/g/h in all the participants; it was 26.51 ± 27.22 nmol/g/h in the men and 36.25 ± 17.90 nmol/g/h in the women. Significant differences were not seen in the fecal ginsenoside Rd-- and CK--forming activities between the men and women. The fecal CK-forming activities of all the study participants were generally proportional to the Rd-forming activities ([Fig. 5](#fig5){ref-type="fig"}A).Table 2The fecal ginsenoside--metabolizing activities of healthy volunteersTable 2GroupGenderGinsenoside-metabolizing activity (nmol/g/h)Rd-forming activityCK-forming activityRGMale51.48 ± 28.3630.25 ± 29.75Female63.18 ± 21.6233.30 ± 23.90Total54.23 26.7830.97 ± 27.80FRGMale42.33 ± 25.1422.77 ± 26.27Female68.53 ± 29.6038.61 ± 14.02Total49.61 ± 54.2327.17 ± 24.22All participants51.65 ± 27.2429.02 ± 25.70[^3]Fig. 5Correlations between the fecal ginsenoside metabolizing activities and the AUCs of the related ginsenosides. (A) Correlation between fecal CK-forming activities and fecal Rd-forming activities in whole subjects; (B) Correlation between the fecal Rd-forming activities and the sum of AUCs of ginsenosides Rd, F2, and CK in whole subjects; (C) Correlation between the fecal Rd-forming activities and the sum of AUCs of ginsenosides Rd, F2, and CK in the FRG-treated group; (D) Correlation between CK-forming activity and the AUC of ginsenoside CK in the FRG-treated group. AUC, area under the serum concentration--time curve; CK, compound K; FRG, fermented red ginseng.Fig. 5

Subsequently, the relationship between the fecal ginsenoside Rd--forming activities and plasma exposure of ginsenoside Rd was investigated. As ginsenoside Rd can be further metabolized to ginsenosides F2 and CK, the plasma exposure was evaluated as the sum of the AUC values of ginsenosides Rd, F2, and CK. The fecal ginsenoside Rd--forming activities did not show a correlation with the sum of the AUC values of ginsenosides Rd, F2, and CK in the whole data set containing both RG and FRG groups ([Fig. 5](#fig5){ref-type="fig"}B). However, when data set was confined to the FRG group, the correlation between the fecal Rd-forming activity and the AUC values of ginsenosides Rd, F2, and CK was statistically significant (r = 0.451, p \< 0.05) ([Fig. 5](#fig5){ref-type="fig"}C). This may be because FRG is higher in ginsenoside Rd content, and the correlation regarding ginsenoside Rd can be shown more clearly in the FRG-treated group. In addition, the AUC value of CK showed an obvious positive correlation (r = 0.550, p \< 0.01) with the fecal CK-forming activity in the FRG group ([Fig. 5](#fig5){ref-type="fig"}D).

For the ginsenosides, metabolic activities of the gut microbiota vary widely among individuals [@bib27]. Our data on the fecal ginsenoside--metabolizing activities also support such interindividual differences; the fecal Rd- and CK-forming activities showed considerable variations among the individuals ([Fig. 5](#fig5){ref-type="fig"}). Meanwhile, the fecal Rd-forming activity and the fecal CK-forming activity showed a good correlation ([Fig. 5](#fig5){ref-type="fig"}A), which indicates that the gut microbiota involved in the formation of Rd may also have acted on the formation of CK. No significant correlations were observed between the fecal metabolizing activities and the pharmacokinetic profiles of the nonpolar ginsenosides in all participants. However, when the analysis data were confined to the FRG group, a significant positive correlation was found. Furthermore, the correlation between the fecal CK-forming activity and the AUC value of CK was more obvious. This may be because biotransformation occurred more actively in the FRG group and the AUC values of Rd, F2, and CK were high enough to measure the correlations as discussed previously. These findings suggest that the pharmacokinetics of ginsenosides Rd, F2, and CK may be affected by the profiles of the gut microbiota.

Several articles reporting the pharmacokinetics of RG in humans have been published [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28]. Most of these articles focused on the pharmacokinetic profiles of ginsenoside CK. According to these articles, fermented ginseng, in general, showed higher serum ginsenoside CK levels than the traditional RG [@bib20], [@bib23], [@bib24]. Nevertheless, these findings have some limitations in explaining how the gut microbiota affects the pharmacokinetics of the ginsenosides, including ginsenoside CK. However, the present study demonstrated the role of the gut microbiota on the pharmacokinetics of the ginsenosides by analyzing the pharmacokinetic profiles of a series of the relevant ginsenoside metabolites and characterizing the relationships between the metabolizing activities of the gut microbiota and the ginsenoside serum levels.

4. Conclusion {#sec4}
=============

In this study, we investigated the pharmacokinetic profiles of protopanaxadiol ginsenosides in humans after the administration of RG extracts (RG and FRG), and then, we analyzed their correlations with the fecal ginsenoside--metabolizing activities. The enzymes of the gut bacteria seemed to exert their metabolic activity mainly on the biotransformation into ginsenoside CK via ginsenoside Rd rather than ginsenoside Rg3. The fecal ginsenoside--metabolizing activities showed positive correlations with the serum levels of the transformed ginsenosides including ginsenoside CK. These findings suggest that the profile and composition of the gut microbiota may affect the bioavailability and, consequently, the pharmacological effects of ginsenosides.
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